Non-small cell lung cancer, RET-positive

From - A Hematology Oncology Wiki
Jump to: navigation, search
Page editor Section editor
Amit Kulkarni.jpg
Amit Kulkarni, MBBS
University of Minnesota
Minneapolis, MN

Social-twitter-icon.png AmitKulkarniMD
Travis Osterman, DO, MS, FAMIA
Vanderbilt University
Nashville, TN

Social-twitter-icon.png TravisOsterman

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

1 regimens on this page
1 variants on this page

Advanced or metastatic disease

Selpercatinib monotherapy

back to top


FDA-recommended dose
Study Evidence
Drilon et al. 2020 (LIBRETTO-001) Phase I/II (RT)

Biomarker eligibility criteria

  • RET fusion positive

Targeted therapy

  • Selpercatinib (Retevmo) with or without food, as follows:
    • Less than 50 kg: 120 mg PO twice per day
    • 50 kg or more: 160 mg PO twice per day

Continued indefinitely


  1. LIBRETTO-001: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. link to original article PubMed NCT03157128